uniQure NV (LTS:0EE0)
$ 6.32 -0.73 (-10.35%) Market Cap: 312.44 Mil Enterprise Value: -55.20 Mil PE Ratio: 0 PB Ratio: 5.60 GF Score: 73/100

Uniqure NV Announces Clinical Update On Gene Therapy for the Treatment of Huntington Disease Transcript

Dec 16, 2021 / 01:30PM GMT
Release Date Price: $21.48 (-20.65%)
Operator

Good day, and thank you for standing by. Welcome to the uniQure conference call. (Operator Instructions)

Please be advised that today's conference is being recorded. (Operator Instructions)

I would now like to hand the conference over to your speaker today, Ms. Maria Cantor, Chief Communications Officer. Ms. Cantor, the floor is yours.

Maria E. Cantor
uniQure N.V. - Chief Communications Officer

Good morning, and thank you for joining us. This morning, uniQure announced initial observations on the first 4 patients enrolled in the ongoing Phase I/II clinical trial of AMT-130 in Huntington's disease. 2 of these 4 patients received AMT-130, and 2 patients experienced an imitation surgical procedure in this randomized blinded study being conducted in the United States. Early observations shared today relate to safety and tolerability at 12 months following AMT-130 administration. Joining me for this investor event and webcast are Matt Kapusta, our Chief Executive Officer; and Dr. Ricardo Dolmetsch, our President of Research and Development.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot